Table 2.
Changes in body mass index in the patients stratified by body mass index at the start of drug therapy
| Duration (months) | Changes in BMI | ||||||
|---|---|---|---|---|---|---|---|
| Met (n = 271) | P‐value | DPP‐4i (n = 271) | P‐value | SU (n = 271) | P‐value | anova (P‐value) | |
| BMI ≥18.5 and <25 | |||||||
| Initiation time | 22.3 ± 1.7 | 22.4 ± 1.6 | 22.1 ± 1.7 | 0.19 | |||
| 3 | 22.2 ± 1.7 | 0.02 | 22.4 ± 1.6 | 0.39 | 22.4 ± 1.8 | 0.00 | 0.44 |
| 6 | 22.2 ± 1.7 | 0.75 | 22.5 ± 1.6 | 0.04 | 22.4 ± 1.8 | 0.00 | 0.30 |
| 9 | 22.3 ± 1.7 | 0.42 | 22.6 ± 1.6 | 0.00 | 22.4 ± 1.8 | 0.00 | 0.14 |
| 12 | 22.3 ± 1.8 | 0.63 | 22.8 ± 1.6 | 0.00 | 22.6 ± 1.9 | 0.00 | 0.02 |
| Met (n = 127) | P‐value | DPP‐4i (n = 127) | P‐value | SU (n = 127) | P‐value | anova (P‐value) | |
|---|---|---|---|---|---|---|---|
| BMI ≥25.0 and <30 | |||||||
| Initiation time | 27.0 ± 1.3 | 26.9 ± 1.3 | 26.8 ± 1.3 | 0.52 | |||
| 3 | 26.6 ± 1.9 | 0.04 | 26.8 ± 1.8 | 0.25 | 26.7 ± 1.4 | 0.68 | 0.73 |
| 6 | 26.7 ± 1.5 | 0.00 | 26.9 ± 1.7 | 0.77 | 26.9 ± 1.6 | 0.84 | 0.71 |
| 9 | 26.8 ± 1.6 | 0.02 | 26.8 ± 1.9 | 0.87 | 26.9 ± 1.6 | 0.94 | 0.92 |
| 12 | 26.6 ± 1.5 | 0.00 | 27.1 ± 1.7 | 0.02 | 26.8 ± 1.6 | 0.37 | 0.41 |
Data are mean ± standard deviation. P value: variables are compared with the value at initiation time by Student's t‐test. anova (P‐value): body mass indexes (BMI) are compared among the patients treated with metformin (Met), dipeptidyl‐peptidase 4 inhibitor (DPP‐4i) or sulfonylurea (SU) by one‐way analysis of variance. BMI is the weight in kilograms divided by the square of the height in meters.